AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03565562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of the e-health tool by local authorities and GPs
Description: In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
Study NCT01954030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO and Bevacizumab
Study NCT01954030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO alone
Study NCT03540979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial preparation for frozen blastocyst transfer
Description: medical endometrial preparation for frozen blastocyte transfer
Study NCT03540979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial preparation for frozen blastocyst transfer
Description: medical endometrial preparation for frozen blastocyte transfer
Study NCT03540979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitor - 2.5mg/d for 5 days
Study NCT03540979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovidrel
Description: recommbinant hCG 250 mcg- single sc injection to induce ovulation
Study NCT03540979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrofem
Description: Estrofem 2mg\*3/d for endometrial preparation
Study NCT03540979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endometrin 100Mg Vaginal Insert
Description: vaginal tab for lutheal support
Study NCT03021876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: treatment with oral L-carnitine, 1500 mg/body per day
Study NCT01608308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: 1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
Study NCT01608308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
Study NCT03401879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
Study NCT03401879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT.
Study NCT03401879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.2mg/kg/body mass)
Description: Rocuronium (0.2mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.2mg/kg/body mass)
Description: Rocuronium (0.2mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.3mg/kg/body mass)
Description: Rocuronium (0.3mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.3mg/kg/body mass)
Description: Rocuronium (0.3mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.45mg/kg/body mass)
Description: Rocuronium (0.45mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.45mg/kg/body mass)
Description: Rocuronium (0.45mg/kg/body mass)
Study NCT02104973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
Study NCT02285556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychological rehabilitation training
Description: The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
Study NCT02285556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical and neurological rehabilitation training
Description: The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
Study NCT02285556 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: rTMS 10HZ high frequency stimulation
Description: Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
Study NCT02285556 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: fake rTMS 10HZ high frequency stimulation
Description: Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
Study NCT01742247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiogel
Description: Application of moisturizer on laser-treated area
Study NCT01742247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: Application of moisturizer on laser-treated area
Study NCT03242824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorodopa
Description: Contrast used in PET
Study NCT03242824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
Study NCT03242824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: imaging test
Study NCT03540979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin 100Mg Vaginal Insert
Description: vaginal tab for lutheal support
Study NCT04597918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
Study NCT02112526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Study NCT02260414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
Study NCT04707326 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir / Lamivudine Pill
Description: HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
Study NCT04534218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: * For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.
Study NCT04534218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg per os, daily, for 6 months
Study NCT04534218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m²/orally twice daily continuously for 6 months
Study NCT04534218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75 mg orally and daily until progression
Study NCT02260414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
Study NCT03321292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine 1000 mg and Acetylesalicylic acid75mg
Description: l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
Study NCT03321292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid 75 mg
Description: acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
Study NCT01254396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Orally Disintegrating Tablet, 50 mg, Single Dose
Study NCT01254396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Orally Disintegrating Tablet, 50 mg, Single Dose
Study NCT02133378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Baxter Hemopatch
Study NCT02133378 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Traditional Hemostasis Techniques (dry or wet gauze compression or similar)
Study NCT04227977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JuxtaFlow System
Description: The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
Study NCT00807547 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergy vaccination (Alutard SQ)
Description: Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
Study NCT00807547 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allergy vaccination (Alutard SQ)
Description: Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WT1 Peptide-Pulsed Dendritic Cells
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Donor Lymphocytes
Description: Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor Lymphocytes
Description: Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-4
Description: water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
Study NCT03021876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual intake
Description: baseliner
Study NCT00004162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00004162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT03401879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA)
Description: Retinal microvasculature will be assessed using OCTA.
Study NCT00004162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT03591965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-008
Description: Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
Study NCT00004162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT03985124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids for Teachers
Description: This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
Study NCT02115776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Description: Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
Study NCT02115776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
Study NCT02115776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
Study NCT02115776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
Study NCT03166527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Immune Globulin 10% Intravenous Solution
Description: standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
Study NCT01152112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomectomy
Description: Removal of fibroids and / or polyps
Study NCT02156453 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: All patients will undergo total knee replacement using midvastus approach by single surgeon.
Study NCT00111696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
Study NCT01299779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-SD
Description: PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients.
Study NCT01299779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS
Description: * 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy
Study NCT04485806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GPS/LM
Description: Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
Study NCT04485806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SPL/LM
Description: Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
Study NCT04485806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GPS/PO
Description: Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
Study NCT04485806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SPL/PO
Description: Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
Study NCT02775903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
Study NCT02775903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
Study NCT01994915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH
Description: Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
Study NCT01196949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manipulative and Rehabilitative Therapy
Description: Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
Study NCT01196949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative Therapy
Description: Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
Study NCT03332264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent Please OTW
Description: Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
Study NCT03332264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eluvia Vascular Stent System
Description: Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
Study NCT02775903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
Study NCT01569763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation
Description: Endometrial Ablation using the Aurora Endometrial Ablation system
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WT1 Peptides
Description: dendritic cell vaccine
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Purified lipopolysaccharide prepared from E.Coli 0:113
Study NCT01569763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rollerball Ablation/Resection
Description: Hysteroscopic rollerball resection/ablation
Study NCT01993784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Study NCT03316534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (100 mg once a day)
Study NCT03316534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin (100 mg once a day)
Study NCT02009449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diphenhydramine
Description: Pre-medication
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pre-medication
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Pre-medication
Study NCT00923910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Pre-medication
Study NCT02354391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate Picato® and MAL PDT day 1, day 5
Description: Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
Study NCT02354391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate Picato® day 2, 3, 4
Description: Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
Study NCT03332264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol stent
Description: Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
Study NCT02354391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAL PDT day 5
Description: Methyl aminolevulate combined with Photodynamic therapy at day 5
Study NCT02991820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
Study NCT02991820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh
Description: Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
Study NCT02828631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Study NCT02828631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Study NCT02828631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pentax videolaryngoscope
Study NCT00794794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine (Clarinex)
Description: Each subject received 5 mL of desloratadine syrup one time
Study NCT00794794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Each subject received 5 mL of cetirizine syrup
Study NCT01073631 — intervention group
Intervention type: DRUG
Intervention: voriconazole tablet
Description: 200 mg PO bid (orally, twice a day)